z-logo
open-access-imgOpen Access
Luspatercept (Reblozyl)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.94
Subject(s) - medicine , anemia , thalassemia , blood transfusion , pediatrics , intensive care medicine , surgery
Clinical evidence suggests that Reblozyl should be reimbursed to treat anemia associated with beta-thalassemia in adults who require blood transfusions on a regular basis if the cost is reduced. Reblozyl is not cost-effective at the submitted price and would require a price reduction of at least 85% to be cost-effective at a $50,000 per quality-adjusted life-year (QALY) threshold. Reblozyl is expected to increase budgets by at least $33,415,422 over 3 years. If the price of Reblozyl is not reduced to a point that is affordable to public payers, this could delay access to the only treatment shown to reduce transfusion burden.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here